These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 9371334

  • 1. Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV purified from Staphylococcus aureus.
    Tanaka M, Onodera Y, Uchida Y, Sato K, Hayakawa I.
    Antimicrob Agents Chemother; 1997 Nov; 41(11):2362-6. PubMed ID: 9371334
    [Abstract] [Full Text] [Related]

  • 2. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
    Gootz TD, Zaniewski RP, Haskell SL, Kaczmarek FS, Maurice AE.
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
    [Abstract] [Full Text] [Related]

  • 3. Mechanism of quinolone resistance in Staphylococcus aureus.
    Tanaka M, Wang T, Onodera Y, Uchida Y, Sato K.
    J Infect Chemother; 2000 Sep; 6(3):131-9. PubMed ID: 11810552
    [Abstract] [Full Text] [Related]

  • 4. Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases.
    Blanche F, Cameron B, Bernard FX, Maton L, Manse B, Ferrero L, Ratet N, Lecoq C, Goniot A, Bisch D, Crouzet J.
    Antimicrob Agents Chemother; 1996 Dec; 40(12):2714-20. PubMed ID: 9124828
    [Abstract] [Full Text] [Related]

  • 5. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.
    Ferrero L, Cameron B, Manse B, Lagneaux D, Crouzet J, Famechon A, Blanche F.
    Mol Microbiol; 1994 Aug; 13(4):641-53. PubMed ID: 7997176
    [Abstract] [Full Text] [Related]

  • 6. Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.
    Ng EY, Trucksis M, Hooper DC.
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1881-8. PubMed ID: 8843298
    [Abstract] [Full Text] [Related]

  • 7. Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
    Cheng J, Thanassi JA, Thoma CL, Bradbury BJ, Deshpande M, Pucci MJ.
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2445-53. PubMed ID: 17502409
    [Abstract] [Full Text] [Related]

  • 8. Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity.
    Fournier B, Hooper DC.
    Antimicrob Agents Chemother; 1998 Jan; 42(1):121-8. PubMed ID: 9449271
    [Abstract] [Full Text] [Related]

  • 9. Action of quinolones against Staphylococcus aureus topoisomerase IV: basis for DNA cleavage enhancement.
    Anderson VE, Zaniewski RP, Kaczmarek FS, Gootz TD, Osheroff N.
    Biochemistry; 2000 Mar 14; 39(10):2726-32. PubMed ID: 10704224
    [Abstract] [Full Text] [Related]

  • 10. Inhibition by quinolones of DNA gyrase from Staphylococcus aureus.
    Tanaka M, Sato K, Kimura Y, Hayakawa I, Osada Y, Nishino T.
    Antimicrob Agents Chemother; 1991 Jul 14; 35(7):1489-91. PubMed ID: 1656864
    [Abstract] [Full Text] [Related]

  • 11. Antibacterial activities and inhibitory effects of sitafloxacin (DU-6859a) and its optical isomers against type II topoisomerases.
    Akasaka T, Kurosaka S, Uchida Y, Tanaka M, Sato K, Hayakawa I.
    Antimicrob Agents Chemother; 1998 May 14; 42(5):1284-7. PubMed ID: 9593169
    [Abstract] [Full Text] [Related]

  • 12. Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates.
    Schmitz FJ, Fluit AC, Brisse S, Verhoef J, Köhrer K, Milatovic D.
    FEMS Immunol Med Microbiol; 1999 Dec 14; 26(3-4):281-7. PubMed ID: 10575140
    [Abstract] [Full Text] [Related]

  • 13. Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV. Changes in drug mechanism across evolutionary boundaries.
    Anderson VE, Zaniewski RP, Kaczmarek FS, Gootz TD, Osheroff N.
    J Biol Chem; 1999 Dec 10; 274(50):35927-32. PubMed ID: 10585479
    [Abstract] [Full Text] [Related]

  • 14. Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus.
    Fukuda H, Hori S, Hiramatsu K.
    Antimicrob Agents Chemother; 1998 Aug 10; 42(8):1917-22. PubMed ID: 9687384
    [Abstract] [Full Text] [Related]

  • 15. Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin.
    Strahilevitz J, Hooper DC.
    Antimicrob Agents Chemother; 2005 May 10; 49(5):1949-56. PubMed ID: 15855518
    [Abstract] [Full Text] [Related]

  • 16. Inhibitory activity of quinolones against DNA gyrase of Mycobacterium tuberculosis.
    Onodera Y, Tanaka M, Sato K.
    J Antimicrob Chemother; 2001 Apr 10; 47(4):447-50. PubMed ID: 11266418
    [Abstract] [Full Text] [Related]

  • 17. Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus.
    Yamagishi J, Kojima T, Oyamada Y, Fujimoto K, Hattori H, Nakamura S, Inoue M.
    Antimicrob Agents Chemother; 1996 May 10; 40(5):1157-63. PubMed ID: 8723458
    [Abstract] [Full Text] [Related]

  • 18. [In vitro activity of new quinolones against clinical strains of Staphylococcus aureus of the wild type and with mutations characterized by gyrA, gyrB and grlA].
    Yagüe Guirao G, Martínez-Toldos MC, Alonso Manzanares MA, Gutiérrez Zufiaurre MN, Martínez-Andrés JA, Muñoz Bellido JL, García-Rodríguez JA, Segovia Hernández M.
    Rev Esp Quimioter; 2000 Sep 10; 13(3):271-5. PubMed ID: 11086276
    [Abstract] [Full Text] [Related]

  • 19. Small-colony mutants of Staphylococcus aureus allow selection of gyrase-mediated resistance to dual-target fluoroquinolones.
    Pan XS, Hamlyn PJ, Talens-Visconti R, Alovero FL, Manzo RH, Fisher LM.
    Antimicrob Agents Chemother; 2002 Aug 10; 46(8):2498-506. PubMed ID: 12121924
    [Abstract] [Full Text] [Related]

  • 20. Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV of Enterococcus faecalis.
    Onodera Y, Okuda J, Tanaka M, Sato K.
    Antimicrob Agents Chemother; 2002 Jun 10; 46(6):1800-4. PubMed ID: 12019093
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.